Business Wire

TX-FLUENCE

Share
Great Northern Hydroponics Projects CA$150,000 in Annual Savings After Fluence LED Implementation

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial food and cannabis production, and Great Northern Hydroponics, an Ontario, Canada-based greenhouse growing more than 10 varieties of tomatoes, announced today that the companies’ collaborative LED implementation is projected to save an estimated 150,000 Canadian dollars in annual operating costs for the greenhouse. The project also qualified for an incentive through the Independent Electricity System Operator’s (IESO) Save on Energy Retrofit program that will significantly reduce the upfront costs of upgrading its lighting technology.

Great Northern Hydroponics’ 70-acre facility produces 20 million pounds of premium tomatoes annually. Its hydroponic greenhouses create optimum growing conditions through a sophisticated climate control system as well as a biologically controlled environment to prevent pest manifestations. Fluence’s LED technology was retrofitted across 10 acres of the facility’s tomato glasshouse. At the helm of Great Northern Hydroponics’ growing operation are Guido van het Hof, the company’s president and general manager, and Dean Bernardes, vice president of operations. Both hold decades of experience growing high-quality crops using the industry’s most advanced cultivation technology.

“We’ve been growing tomatoes for more than 20 years,” Van het Hof said. “As one of the first growers in our region to illuminate crops in a commercial environment, we’ve been immersed in researching and optimizing spectral strategies for plant growth and quality. Since the onset of LED technology, I’ve been particularly curious about how broad-spectrum LEDs could affect plant development. Based on our years of research and trialing, we’ve discovered that crops grow beautifully—with higher yields and fruit weights—under broad-spectrum light.”

Van het Hof’s multiyear commitment to researching the latest advancements and strategies for LED horticulture lighting rivals leading research universities and some of the world’s largest cultivators. In his pursuit to identify the optimal spectral strategy for vine crop production, Van het Hof spearheaded various trials with high-pressure sodium fixtures as well as LED technology. Throughout his decade-long exploration, Van het Hof has recorded significant advantages under broad-spectrum LED technology, reporting an increase in biomass and fruit production as well as significant energy savings—reductions which enabled the Great Northern Hydroponics team to leverage the Save on Energy Retrofit program offering growers incentives for energy-efficient lighting upgrades.

“Great Northern Hydroponics has always been a pioneer in leveraging horticulture technology and innovative cultivation methods,” said Steve Graves, vice president of business development for Fluence and long-time collaborator with Van het Hof. “Our work with Guido has informed some of our most important product advancements for vine crop growers throughout the world. Guido and his team at Great Northern Hydroponics have reinforced the validity and efficacy of LED lighting in greenhouse environments.”

Through Fluence’s utility rebate coordination program, the company assists growers with identifying, applying for and, in some cases, creating rebate programs in a facility’s respective region. With Great Northern Hydroponics’ lighting upgrade supported by the Save on Energy Retrofit program incentive, Van het Hof estimates the business will save approximately CA$150,000 in annual operational costs by replacing its high-pressure sodium lighting with Fluence’s LED technology.

“LED technology is proving to be superior across all categories,” Van het Hof added. “Our plants are flourishing under broad-spectrum lighting, our operational costs are decreasing and our staff is enjoying working with white light versus harsher, redder lights. It’s a win-win for everyone.”

For more information on Fluence and its rebate services, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye